Roche APAC Vision Health Survey

Of the 2.2 billion people worldwide suffering from vision impairment, two-thirds of those experiencing moderate to severe impairment reside in Asia Pacific¹. In the face of a rapidly ageing society and rise in diabetes rates, the APAC Vision Health Survey uncovers the current state of vision health providing critical insights towards developing sustainable solutions.

More Than Numbers:
A Human Crisis

New survey across eight APAC markets reveals crucial gaps in vision care: despite widespread awareness, preventive care remains critically low, highlighting the need for system-level change as populations age and
diabetes rates rise.

Addressing these barriers will help enable sustainable vision health for all.

New survey across eight APAC markets reveals crucial gaps in vision care: despite widespread awareness, preventive care remains critically low, highlighting the need for system-level change as populations age and diabetes rates rise.

Addressing these barriers will help enable sustainable vision health for all.

Research details:

The APAC Vision Health Survey 2024 was commissioned by Roche and conducted by GWI between August to September 2024. The research engaged 4,354 adults aged 40+ across Australia [502], Hong Kong [476], Malaysia [607], the Philippines [478], Singapore [604], South Korea [510], Taiwan [570], and Thailand [607].

Disclaimers

- All figures are rounded to the nearest whole number
- Vision impairment is defined in the survey as significant or permanent loss of vision
- Regular eye check is defined as annual or more frequent examinations
M-SG-00001893 | January 2025

Additional Resources

Explore our resources to gain further insights into the Roche APAC Vision Health Survey and its impactful findings.

Roche is committed to improving the quality of life for those living with conditions that affect their vision through pioneering therapies and innovative solutions.

Find out more about our efforts here.

All contents on the website are for general information only and Roche disclaims all express and implied warranties with respect to these contents.
M-SG-00001894-Mar-2025